Gary Goodman, MD
Pediatric Allergy/Immunology · Saint Louis, MONPI 1811999485
Payments from drug & device makers
Across 456 payments — averaging $118.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$47K
- GSK$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$616
- CSL Behring$460
- Takeda Pharmaceuticals U.S.A., Inc.$399
- plus $3K from 28 others
What the payments were for
- Consulting fees$1,5533%
- Speaking & faculty fees$40,29075%
- Travel & lodging$4,3028%
- Food & beverage$7,66514%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 62 | $47,144 |
| GSK | 93 | $1,679 |
| AstraZeneca | 62 | $1,079 |
| Regeneron Healthcare Solutions, Inc. | 28 | $616 |
| CSL Behring | 23 | $460 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $399 |
| Sanofi | 20 | $348 |
| Optinose US, Inc. | 20 | $282 |
| Grifols USA, LLC | 13 | $264 |
| Genentech USA, Inc. | 12 | $211 |
| Novartis | 11 | $187 |
| Pfizer | 11 | $184 |
| Teva Pharmaceuticals USA, Inc. | 23 | $165 |
| Kaleo, Inc. | 7 | $120 |
| AbbVie | 4 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $75 |
| Amgen | 3 | $71 |
| Kedrion Biopharma, Inc. | 3 | $62 |
| Blueprint Medicines Corporation | 3 | $56 |
| Hikma Pharmaceuticals USA | 3 | $48 |
| Bio Products Laboratory USA, Inc. | 3 | $44 |
| Eyevance Pharmaceuticals LLC | 3 | $43 |
| GC Biopharma USA, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $31 |
| ADMA Biomanufacturing LLC | 1 | $23 |
| LEO Pharma Inc. | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Merck | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,948 in reported general payments places this provider in the 80th percentile of 22 pediatric allergy/immunology providers in Missouri.
See all pediatric allergy/immunology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $94,864 |
| Dupixent SyringeDupilumab | 11 | $41,164 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $21,038 |
| Spiriva RespimatTiotropium Bromide | 13 | $14,276 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,727 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,819 |
| DuleraMometasone/Formoterol | 13 | $4,911 |
| Epinephrine | 26 | $4,406 |
| Azelastine Hcl | 88 | $4,028 |
| Pulmicort FlexhalerBudesonide | 15 | $3,957 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $3,594 |
| Mometasone Furoate | 20 | $2,758 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,742 |
| Ipratropium Bromide | 81 | $2,669 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 15 | $2,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $460 | $94,86416 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,679 | $30,59852 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $1,079 | $11,68435 claims |
| MerckDulera | $17 | $4,91113 claims |
| Hikma Pharmaceuticals USAEpinephrine | $48 | $4,40626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 22 pediatric allergy/immunology providers in Missouri.
Other pediatric allergy/immunology in Saint Louis
- Deepika PolineniSaint Louis$852K
- William JohnsonSaint Louis$748K
- Ronald RubensteinSaint Louis$593K
- Ray DavisSaint Louis$14K
- Lisa SuffianSaint Louis$5K
- Alan KnutsenSaint Louis$3K
- Rebekah BrowningSaint Louis$1K
- Caroline HornerSaint Louis$742
- Brooke PolkSaint Louis$711
- Alysa EllisSaint Louis$682
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.